TrialScope Adds Another Clinical Trial Sponsor to Growing Customer Base
JERSEY CITY, N.J., May 28, 2015 – TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced that it is adding another clinical trial sponsor to its growing client list for the PharmaCM clinical trial disclosure platform. The latest sponsor to join TrialScope’s client list selected the PharmaCM platform to replace an existing commercial product that had been previously implemented.
The new account represents continued growth for TrialScope since the company acquired the PharmaCM platform in June 2014. Currently, over 8,000 users around the world are managing almost 30,000 clinical trial registrations using the PharmaCM platform.
Mike Forgash, CEO, TrialScope, commented, “The TrialScope team looks forward to working with a new sponsor team and adding to its growing roster of satisfied clients. Our expanding customer base is a testament to the simplicity, efficiency and overall value that our zero-footprint solutions bring to complex clinical trial disclosure processes. Our team’s strong reputation for depth of knowledge and breadth of experience is attractive to clients of all sizes who are looking to stay ahead of the curve regarding ever-changing global regulatory requirements and need a disclosure-driven solution as opposed to simply a technology. This is especially important as emerging regulations (such as the EU Clinical Trials Regulation) add complexity to global trial disclosure processes.”
Thomas Wicks, Chief Strategy Officer, noted that the TrialScope team is leveraging its “Rapid Path to Compliance,” a proven engagement methodology based on collaboration and compliance and focused on quickly implementing the PharmaCM platform and decreasing the client’s time to productivity. He added, “As new clients come aboard, we have a unique chance to partner with them to transform their business practices and lower risks of non-compliance. Our practical knowledge is baked into our Rapid Path to Compliance methodology so clients get the combined benefits of our experience and our technology platform to simplify compliance and increase productivity.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
